← Statins × cardiovascular events

TrialAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2007

Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

Michel Chonchol et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 4,444 people · 2007

Randomised comparison

Reduced cardiovascular events

−33%−44% to −21%

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.67, 95% CI 0.56–0.79

Randomised comparison

Reduced cardiovascular events

−38%−51% to −23%

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.62, 95% CI 0.49–0.77

Range includes no effect

No clear effect on cardiovascular events

−12%−45% to +39%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 0.88, 95% CI 0.55–1.39

Three numbers in the abstract

the abstract, start to end

… of major coronary events (adjusted HR, 0.67; CI, 0.56 to 0.79) and coronary revascularization (adjusted HR, 0.62; CI, 0.49 to 0.77) also were …

… in the simvastatin group (adjusted HR, 0.88; CI, 0.55 to 1.39).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.670.56–0.79
Cardiovascular events
HR 0.620.49–0.77
Cardiovascular events
HR 0.880.55–1.39
StatinsCardiovascular events
1 / 4

21 papers cite it

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 17336698